The Development and Validation of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma: The Functional Assessment of Cancer Therapy—Lymphoma (FACT-Lym)

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Unknown venue

• Publication date

  2013-02-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1155/2013/147176
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Are psychosocial factors associated with quality of life in patients with haematological cancer? A critical review of the literature

  2013cited by this paper
• Economic Burden of Follicular Non-Hodgkin’s Lymphoma

  2012cited by this paper
• Quality of life after chemotherapy or hematopoietic cell transplant in follicular lymphoma: what's next?

  2012cited by this paper
• Quality of life domains among non-Hodgkin lymphoma survivors: an integrative literature review

  2011cited by this paper
• Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily

  2011cited by this paper
• Quality of life research: adding an important dimension to the evaluation of therapeutic outcomes

  2011cited by this paper
• Cancer statistics, 2011

  2011cited by this paper
• Post-traumatic stress symptoms in long-term non-Hodgkin's lymphoma survivors: does time heal?

  2011cited by this paper
• The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin’s and non-Hodgkin’s lymphoma survivors

  2011cited by this paper
• Quality of life following treatment for B-cell lymphoma

  2011cited by this paper
• An Exploratory Model of the Relationships Between Cancer-Related Trauma Outcomes on Quality of Life in Non-Hodgkin Lymphoma Survivors

  2010cited by this paper
• Cost Effectiveness of Rituximab Maintenance Therapy in Follicular Lymphoma

  2010cited by this paper
• Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up

  2010cited by this paper
• Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden

  2008cited by this paper
• The impact of follicular lymphoma on health-related quality of life.

  2008cited by this paper
• PCN29 COST-EFFECTIVENESS OF MAINTENANCE RITUXIMAB TREATMENT AFTER SECOND LINE THERAPY IN PATIENTS WITH FOLLICULAR NON-HODGKIN'S LYMPHOMA IN SWEDEN

  2007cited by this paper
• Development of a Measure of Health-Related Quality of Life for Non-Hodgkin’s Lymphoma Clinical Research: The Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym).

  2005cited by this paper
• Treatment of follicular non-Hodgkin's lymphoma.

  2005cited by this paper
• SF-36 health survey: Manual and interpretation guide

  2003cited by this paper
• Rituximab in the treatment of diffuse large B-cell lymphomas.

  2002cited by this paper
• Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system.

  2002cited by this paper
• Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).

  2002cited by this paper
• Challenges in treating hematologic malignancies.

  2002cited by this paper
• Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

  2002cited by this paper
• Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study

  2001cited by this paper
• Very low toxicity and good quality of life in 48 elderly patients autotransplanted for hematological malignancies: a single center experience

  2001cited by this paper
• Cost analysis and quality of life assessment comparing patients undergoing autologous peripheral blood stem cell transplantation or autologous bone marrow transplantation for refractory or relapsed non-Hodgkin's lymphoma or Hodgkin's disease. a prospective randomised trial.

  2001cited by this paper
• Quality of life in adult patients after stem cell transplantation.

  2000cited by this paper
• Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease.

  2000cited by this paper
• Quality of life in patients with low-grade non-Hodgkin's lymphoma.

  1998cited by this paper
• Lymphomas: long-term sequelae and survivorship issues.

  1998cited by this paper
• The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

  1993cited by this paper
• Professional rehabilitation of lymphoma patients: a study of psychosocial factors associated with return to work

  1993cited by this paper
• Treatment‐related morbidity in patients with lymphoma

  1991cited by this paper
• Non-Hodgkin's lymphoma.

  1989cited by this paper
• Measurement of health status. Ascertaining the minimal clinically important difference.

  1989cited by this paper
• Cancer statistics

  1989cited by this paper
• A brief POMS measure of distress for cancer patients.

  1987cited by this paper
• [Malignant lymphomas].

  1985cited by this paper
• A new scale of social desirability independent of psychopathology.

  1960cited by this paper
• Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide

  1960cited by this paper
• Coefficient alpha and the internal structure of tests

  1951cited by this paper

• Real-world evaluation of health-related quality of life in hematology patients treated with rituximab: results of a multicentric cross-sectional cohort study

  2026cites this paper
• Patient-reported outcomes: a Polaris for POLARIX.

  2026cites this paper
• Patient-reported outcomes of CAR T-cell therapy in non-Hodgkin Lymphoma patients and their impact on survival.

  2025cites this paper
• Patient-reported outcomes in relapsed/refractory diffuse large B-cell lymphoma with odronextamab monotherapy

  2025cites this paper
• Patient and physician treatment preferences in relapsed/refractory follicular lymphoma: a discrete choice experiment in the United States, United Kingdom, France, Germany, Brazil, and Japan

  2025cites this paper
• Heterogeneity and associated factors of information needs among patients with hematological malignancies in China: a latent profile analysis

  2025cites this paper
• Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study.

  2025cites this paper
• Patient-Reported Outcome Measures (PROMS) in Lymphoma

  2025cites this paper
• Ensuring relevance and equity in patient reported outcomes (PROs) in endometrial cancer: The SGO promote study (Patient Reported Outcomes Measurement Opportunities Through Equity).

  2025cites this paper
• Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study

  2025cites this paper
• Unmet Needs and Health‐Related Quality of Life Among Patients With Relapsed/Refractory Indolent Non‐Hodgkin Lymphoma: A Mixed‐Methods Study

  2025cites this paper
• Fear of Cancer Recurrence and Associated Factors in Lymphoma Survivors and Their Family Caregivers: A Cross‐Sectional Study

  2025cites this paper
• Exploring the link between unmet needs and quality of life in lymphoma survivors: a cross-sectional study

  2025cites this paper
• Patient-reported outcomes in Hodgkin lymphoma trials: a systematic review

  2024cites this paper
• Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial.

  2024cites this paper
• SOHO State of the Art Updates and Next Questions | Measuring Patient-Reported Outcomes (PROs) and Treatment Tolerability in Patients With Hematologic Malignancies.

  2024cites this paper
• Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.

  2024cites this paper
• Remission after CAR T‐cell therapy: Do lymphoma patients recover a normal life?

  2024influential citation
• Investigator choice of standard therapy versus sequential novel therapy arms in the treatment of relapsed follicular lymphoma (REFRACT): study protocol for a multi-centre, open-label, randomised, phase II platform trial

  2024cites this paper
• The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes

  2024cites this paper
• Effectivity of Palliative Care Bundle on Advanced Gallbladder Cancer: A Randomised Controlled Trial

  2023influential citation
• Personalized approaches for treatment-naïve mantle cell lymphoma

  2023cites this paper
• FACTORS ASSOCIATED WITH LONG-TERM FUNCTIONAL AND PSYCHOSOCIAL OUTCOMES IN PATIENTS WITH NON-HODGKIN LYMPHOMA

  2023cites this paper
• Monitoring multidimensional aspects of quality of life after cancer immunotherapy: protocol for the international multicentre, observational QUALITOP cohort study

  2023cites this paper
• Psychometrics of patient-reported bother from side effects of treatment single-items in industry-sponsored oncology trials

  2023cites this paper
• Patient-reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic review

  2023cites this paper
• Improvements in Patient-Reported Outcomes in Relapsed or Refractory Large B-Cell Lymphoma Patients Treated With Epcoritamab.

  2023cites this paper
• Content comparison of unmet needs self-report measures for lymphoma cancer survivors: A systematic review

  2023influential citation
• Symptom clusters and predominant symptoms in lymphoma survivorship: a cross-sectional study using trend analysis

  2023cites this paper
• Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

  2022cites this paper
• Patient‐reported outcomes provide prognostic information for survival in patients with diffuse large B‐cell lymphoma: Analysis of 1239 patients from the GOYA study

  2022cites this paper
• Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL

  2022cites this paper
• Longitudinal assessment of quality of life in indolent non-Hodgkin lymphomas managed with active surveillance

  2022cites this paper
• Effects of high-intensity interval training on health-related quality of life in chronic lymphocytic leukemia: A pilot study.

  2022cites this paper
• Worsening Quality of Life in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients in Active Surveillance: A 12-Month Longitudinal Study.

  2021cites this paper
• Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.

  2021cites this paper
• Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

  2021cites this paper
• Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.

  2021cites this paper
• Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study

  2020cites this paper
• Validation of the FACT-Lym scale to measure quality of life in Colombian patients with lymphoma

  2020cites this paper
• Partnering with general practitioners to optimize survivorship for patients with lymphoma: a phase II randomized controlled trial (the GOSPEL I trial)

  2020cites this paper
• Biometrics and quality of life of lymphoma patients: A longitudinal mixed‐model approach

  2020cites this paper
• Symptom Clustering and Its Effect on Functional Status in Lymphoma Patients

  2020cites this paper
• Qualitative Findings on the Impact of Disease in Epstein–Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Patients, as Measured by EQ-5D, SF-36, and the FACT-LYM

  2020cites this paper
• Validación de la escala FACT-Lym para la evaluación de la calidad de vida en pacientes colombianos con linfoma

  2020cites this paper
• Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L

  2020cites this paper
• Nutritional status and quality of life of patients with lymphoma

  2019cites this paper
• An Approach to Assess Quality of Life Through Biometric Monitoring in Cancer Patients

  2019cites this paper
• Home-Based Yoga Program for the Patients Suffering from Malignant Lymphoma during Chemotherapy: A Feasibility Study

  2018cites this paper
• Haematological malignancy: Are we measuring what is important to patients? A systematic review of quality‐of‐life instruments

  2018cites this paper
• The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma

  2017cites this paper
• Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

  2017influential citation
• Health-related quality of life in patients with indolent and aggressive non-Hodgkin lymphoma

  2016cites this paper
• ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma

  2016cites this paper
• Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

  2016cites this paper
• The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma

  2016cites this paper
• Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

  2015cites this paper
• Cognitive Dysfunction in non-Hodgkin's Lymphoma Patients Treated with Front-Line Chemotherapy

  2015cites this paper
• A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy – Lymphoma Symptom Index

  2013cites this paper